DividendAugust 19, 2026

Dividend Win Wednesday: Six Insiders Buy While Energy Names Pay 2.6% at Highs

Top 5 Pixie Picks

This Week's Setup

Greed is running at 57 on the Fear & Greed index while the S&P 500 CAPE holds at 38.9, a level that has historically marked the upper boundary of sustainable equity valuations. Within that backdrop, the dividend screen is surfacing eight names with free cash flow yields between 4.4% and 11.3%, drawdowns ranging from flat to 17%, and insider activity split between energy executive selling and pharma management buying.

ConocoPhillips and Novartis anchor the top two Pixie Ranks, both trading less than 10% off their 52-week highs with dividend yields above 2.5% and payout ratios near 50–65%.

Quick Scan

#	Ticker	One-line thesis
1	COP	Energy FCF at 4.6%, near highs, Morgan Stanley $151 target
2	NVS	Pharma with 5.2% FCF yield, 9% drawdown, cardiovascular leadership
3	NEM	Gold at 12% drawdown, 5.8% FCF yield, $143 consensus target
4	EOG	Energy at 2.6% drawdown, 4.4% FCF yield, insider selling
5	BIIB	Biotech at new highs, 6.3% FCF yield, insider buying
6	CI	Health insurer at 17% drawdown, 11.3% FCF yield, $342 target
7	GSK	UK pharma at 17% drawdown, 4.7% FCF yield, pipeline expansion
8	GILD	HIV franchise at 9.6% drawdown, 5.4% FCF yield, insider activity

The 8 Names

1. ConocoPhillips (COP)

Dividend yield: 2.6% | Payout ratio: 51.3% | 52w drawdown: -4.8%

The setup here is a 4.6% free cash flow yield on a stock trading 4.8% off its 52-week high with a 13.5% return on invested capital and an earnings yield of 4.6%. Payout cover is 1.8x, and the company is generating gross margins of 25.1% while growing revenue 7.7% year-over-year.

Insider activity in July shows three Form 4 filings from Silvina Vatnick and Sylvia Escovar Gomez, though transaction amounts are not disclosed in the structured data. Morgan Stanley raised the price target to $151 from $147, maintaining an Overweight rating, implying 16.8% upside from the current $129.35 price.

The yield spread is negative at -0.2%, meaning the earnings yield trails the 10-year Treasury, and the stock carries a 21.96 P/E on an EV/EBITDA multiple of 6.76 in an energy sector exposed to commodity price volatility.

2. Novartis AG (NVS)

Dividend yield: 3.1% | Payout ratio: 64.7% | 52w drawdown: -9.3%

Novartis offers a 5.2% free cash flow yield at a 9.3% drawdown with a 16.0% return on invested capital, 9.6% revenue growth year-over-year, and gross margins of 75.8%. The company's five-year dividend growth rate is 7.2%, and payout cover is 1.7x free cash flow yield.

Novartis released data at the ESC Congress 2026 reinforcing cardiovascular leadership and showcasing next-generation therapies, a catalyst for a portfolio that generated an EV/EBITDA of 13.89. News also surfaced interest from the company in clinical-stage cancer assets alongside Eli Lilly and Bristol Myers.

The analyst consensus price target of $153.87 sits 0.4% below the current $154.54 price, implying no upside, and the stock trades at a 22.14 P/E with a 7.66 price-to-book ratio.

3. Newmont Corporation (NEM)

Dividend yield: 0.9% | Payout ratio: 15.7% | 52w drawdown: -12.3%

Newmont trades at a 12.3% drawdown with a 5.8% free cash flow yield, a 29.9% return on invested capital, and 21.3% revenue growth year-over-year. The company carries net cash, reflected in a negative -0.20 net debt to EBITDA ratio, and an interest coverage ratio of 50.5x.

Insider selling in July and August includes transactions from Peter Toth, Mark Rodgers, and Brian Tabolt, though dollar amounts are not provided. Newmont announced the sale of the Northumberland Gold Project to StrikePoint, a portfolio simplification move.

The 0.9% dividend yield is the lowest on this screen, and the payout ratio of 15.7% signals capital allocation priorities tilted toward reinvestment rather than shareholder income, despite a 15.34 P/E and a $142.82 consensus target implying 20.8% upside.

4. EOG Resources, Inc. (EOG)

Dividend yield: 2.8% | Payout ratio: 43.6% | 52w drawdown: -2.6%

EOG offers a 4.4% free cash flow yield on a stock trading 2.6% off its 52-week high with a 15.2% return on invested capital and a 6.9% earnings yield. The company maintains an interest coverage ratio of 28.1x and a net debt to EBITDA of 0.35, among the cleanest balance sheets in the energy sector.

Revenue declined 3.4% year-over-year, and gross margins of 63.4% trail some peers. The EV/EBITDA multiple of 6.14 is compressed, but the yield spread of 2.2% offers a cushion against the 10-year Treasury.

Insider activity in August shows three Form 4 filings from Christopher Gaut, Charles Crisp, and Janet Clark, all documented as sells totaling 14,343 net shares over six months. Morgan Stanley, Barclays, and Capital One all adjusted price targets downward in recent weeks, with consensus now at $160.25, implying 8.3% upside.

5. Biogen Inc. (BIIB)

Dividend yield: N/A | Payout ratio: 0.0% | 52w drawdown: +2.9%

Biogen trades at a new 52-week high with a 6.3% free cash flow yield, a 22.80 P/E, and a 7.0% return on invested capital. Revenue growth is 2.2% year-over-year, and gross margins are 75.7%, characteristic of a pharma franchise with pricing power.

Insider buying over the past six months totals 3 net shares across 10 transactions, all buys with zero sells, including a recent Form 4 from Lloyd Minor in August. Wolfe Research upgraded Biogen to Outperform from Peer Perform with a $300 price target, citing pipeline strength and valuation.

The company pays no dividend, making it an outlier on a dividend-focused screen, and the payout ratio is 0.0%. The earnings yield spread is negative at -0.3%, and net debt to EBITDA of 0.64 is serviceable but not exceptional.

Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Dividend stocks.

6. The Cigna Group (CI)

Dividend yield: 2.2% | Payout ratio: 27.7% | 52w drawdown: -17.0%

Cigna trades at a 17.0% drawdown with an 11.3% free cash flow yield, the highest on this screen, and a 40.4% earnings yield. The 2.47 P/E ratio reflects accounting treatment of the insurance float, and the company generates an 11.2% return on invested capital with 11.7% revenue growth year-over-year.

Three Form 4 filings in July and August from James Lee and Nicole Jones indicate insider transactions, though dollar amounts are not disclosed. The company reported Q2 earnings outperformance driven by improved health care benefits profitability, and the consensus price target of $341.50 implies 21.4% upside.

The stock carries a 1.72 net debt to EBITDA ratio and an interest coverage ratio of 6.53, lower than peers, and the shareholder yield of 5.0% includes both dividends and buybacks but reflects elevated capital return needs.

7. GSK plc (GSK)

Dividend yield: 3.5% | Payout ratio: 63.2% | 52w drawdown: -17.4%

GSK trades at a 17.4% drawdown with a 4.7% free cash flow yield, a 19.9% return on invested capital, and a 7.5% earnings yield. The company maintains 72.4% gross margins and 4.1% revenue growth year-over-year, with an interest coverage ratio of 11.8x.

The five-year dividend growth rate is negative 15.6%, a legacy of portfolio restructuring, and the stock trades at an 18.67 EV/EBITDA multiple, elevated for a UK-listed large cap. The yield spread is 2.8%, providing some valuation cushion, but the $57.94 consensus target implies 13.6% upside from a stock that has underperformed.

News coverage highlights GSK's pipeline acceleration and questions whether it unlocks a new growth era, positioning the company alongside Gilead as a beneficiary of HIV portfolio expansion themes.

8. Gilead Sciences, Inc. (GILD)

Dividend yield: 2.3% | Payout ratio: 47.9% | 52w drawdown: -9.6%

Gilead offers a 5.4% free cash flow yield at a 9.6% drawdown with a 24.4% return on invested capital, 2.4% revenue growth, and gross margins of 78.8%. The company trades at a 19.35 P/E with a 5.2% earnings yield and an 11.88 EV/EBITDA multiple.

Insider activity in August includes a Form 4 filing from CEO Daniel O'Day and two other executives, with Andrew Dickinson selling shares worth $3,853,908 according to an SEC filing. News highlights Gilead's expanding HIV portfolio as a potential growth catalyst.

The yield spread is 0.5%, narrow but positive, and net debt to EBITDA of 0.84 is serviceable but not exceptional. The $157.83 consensus target implies 11.0% upside, but the stock's one-year trend is flat at 0.07%.

What to Watch

• ConocoPhillips and EOG Resources earnings in late October will clarify whether energy FCF generation can sustain current payout ratios amid commodity price volatility and capex discipline.

• Novartis cardiovascular data follow-up from the ESC Congress 2026 conference may drive revaluation if next-generation therapies advance toward regulatory milestones in Q4.

• Cigna Q3 earnings in early November will test whether the health care benefits profitability improvement that drove Q2 outperformance is durable or cyclical.

• Biogen pipeline updates from Wolfe's Outperform upgrade thesis, particularly late-stage neurology and Alzheimer's programs, could shift sentiment on a stock trading at new highs with no dividend.

Go Deeper

The dividend screener ranks companies by sustainable yield, payout cover, and cash generation strength, filtering for quality franchises at entry points.

Check out the full screener →

Pro-only analytics

Named tickers from this article open in the app with Pro or an active trial.

Stock Pixie Pro

See the full dividend screen — every pick, every metric, every day.

The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.

Start your free trial →

Or start with the free Market Brief Digest

Where the market stands before the open, in plain language, every trading day. No account needed.

About the Stock Pixie Score

The Stock Pixie Score is a 0–10 composite that measures how well a stock matches the criteria for that screen. Scores reflect the strength of quantitative signals across valuation, quality, and trend factors weighted for the specific screener. A higher score means stronger alignment; above 8 indicates the algorithm finds the setup compelling across most of the metrics it tracks. It is a filter, not a forecast.

The Fine Print

Stock Pixie is not a registered investment adviser and does not offer financial advice. It is a stock screening platform that scores and ranks stocks using quantitative signals. You are responsible for your own research and investment decisions. Past performance does not guarantee future results.